PepGen Inc
PEPG4.210USD
-0.330-7.27%
Handelsschluss 11/06, 16:00（ET）Kurse um 15 Minuten verzögert
138.09MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PepGen Inc Unternehmen
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
PepGen Inc Informationen
BörsenkürzelPEPG
Name des UnternehmensPepGen Inc
IPO-datumMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Anzahl der mitarbeiter81
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse245 Main St, 2nd Floor
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon17034568000
Websitehttps://pepgen.com
BörsenkürzelPEPG
IPO-datumMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Führungskräfte von PepGen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Point72 Asset Management, L.P.
4.01%
Millennium Management LLC
2.20%
Andere
52.32%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Point72 Asset Management, L.P.
4.01%
Millennium Management LLC
2.20%
Andere
52.32%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
36.40%
Hedge Fund
12.46%
Investment Advisor/Hedge Fund
5.92%
Investment Advisor
2.67%
Sovereign Wealth Fund
1.81%
Research Firm
0.25%
Individual Investor
0.13%
Andere
40.36%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
157
40.91M
59.52%
+1.09M
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
20.06M
29.19%
+9.38M
+87.70%
Sep 26, 2025
Oxford Science Enterprises PLC
4.96M
7.21%
+200.00K
+4.21%
Sep 30, 2025
Viking Global Investors LP
3.48M
5.07%
+2.00M
+134.91%
Sep 26, 2025
Point72 Asset Management, L.P.
2.76M
4.01%
+83.23K
+3.11%
Jun 30, 2025
Millennium Management LLC
1.51M
2.2%
+476.18K
+46.10%
Jun 30, 2025
Adage Capital Management, L.P.
1.35M
1.96%
--
--
Jun 30, 2025
Qatar Investment Authority
1.24M
1.81%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
937.02K
1.36%
+37.29K
+4.14%
Jun 30, 2025
Laurion Capital Management LP
810.76K
1.18%
--
--
Jun 30, 2025
Woodline Partners LP
691.53K
1.01%
-89.37K
-11.44%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 17 hours ago
Aktualisiert: 17 hours ago
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Micro-Cap ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0.02%
iShares Micro-Cap ETF
Anteil0.02%
Invesco Nasdaq Biotechnology ETF
Anteil0.02%
iShares Biotechnology ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
